Navigation Links
BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming,Clinical Conferences

JERUSALEM--(BUSINESS WIRE)--May 17, 2007 - BioLineRx Ltd. (TASE: BLRX), Israel's leading drug development company, announced today that abstracts containing data from its successfully completed phase I clinical trails of BL-1020, first in class GABA-enhanced antipsychotic for the treatment of schizophrenia, have been accepted for poster presentations at three leading scientific conferences. The data will be presented at the following conferences:

-- Society of Biological Psychiatry Annual Convention, May 17-19 (San Diego)

-- American Psychiatric Association Annual Meeting, May 19-24 (San Diego)

-- New Clinical Drug Evaluation Unit Annual (NCDEU) Meeting, June 11-14 (Boca Raton)

The abstract which has been selected for these poster presentations describes the results of a Phase I, randomized, placebo-controlled double blinded, single dose-escalation study to evaluate the safety and determine the pharmacokinetic profile of BL-1020, first in class GABA-enhanced antipsychotic for the treatment of schizophrenia.

"We are very pleased that these important data regarding the Phase I trials of BL-1020 are being presented at these three major psychiatric conferences. The Phase I studies support our product profile of a highly efficacious antipsychotic devoid of extrapyramidal symptoms or metabolic side effects," commented Morris Laster, chief executive officer of BioLineRx. "We continue to believe that the compound holds great promise for the treatment of schizophrenia, which currently poses an intractable medical problem for physicians and patients. We very much look forward to the initiation of the Phase II trial in the second quarter of 2007."

About BL-1020

BL-1020 is an orally available GABA enhanced antipsychotic clinical candidate for the treatment of schizophrenia. Data from preclinical and phase I studies demonstrated that the compound may retain the efficacy of currently
'"/>




Page: 1 2 3

Related medicine technology :

1. BioLineRx Presents Data From Successful Phase I Trial for BL-1020 in Schizophrenia at American Psychiatric Association Conference
2. BioLineRx Presents Data on BL-1040 at Cardiovascular Revascularization Therapies Conference Demonstrating Potential to Reduce Deterioration of Infarcted Heart Tissue and Maintain Functionality
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
(Date:6/30/2015)... June 30, 2015  The MEDevice San Diego Conference, ... an event dedicated to bringing medtech professionals together for ... topics affecting the industry today. This year,s conference will ... and opportunities facing today,s medtech professional in a fun, ... register for MEDevice San Diego, please visit: MEDeviceSD.com. ...
(Date:6/30/2015)... , June 30, 2015 Zynerba Pharmaceuticals, Inc. ... Form S-1 with the U.S. Securities and Exchange Commission (SEC) ... stock. The number of shares to be offered and the ... Jefferies LLC and Piper Jaffray & ... and Canaccord Genuity Inc. and Oppenheimer & Co. Inc. will ...
(Date:6/30/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/54fkmt/global_array ... "Global Array Instruments Market 2015-2019" report to ... market to grow at a CAGR of 12.48 ... array instruments market can be divided into three ... tissue microarrays and cell microarrays. This report covers ...
Breaking Medicine Technology:MEDevice San Diego 2015 Attracts High-Tech Medical Industry 2Zynerba Files Registration Statement for Proposed Initial Public Offering of Common Stock 2Global Array Instruments Market 2015-2019 - Advances in Personalized Medicines with Affymetrix, Agilent Technologies & Illumina Dominating 2
(Date:7/1/2015)... Wis. (PRWEB) , ... July 01, 2015 , ... ... identification (RFID) safety and security solutions, has partnered with WIU Crossroads School in ... Duress Solution. The unique AEDY (Alternative Education for Disruptive Youth) environment of Crossroads ...
(Date:7/1/2015)... ... ... Recent research has revealed that most adults lack confidence in the effectiveness of ... the last Monday of June, Whiter Image Dental will help new dental ... customer’s first popular In-Office 2 Patient Kit. , The In-Office 2 ...
(Date:7/1/2015)... ... 2015 , ... Seldon Technologies, a leading developer of water ... manufacturer, Bebederos Ecologicos / Ottone Meloda to provide clean drinking water to millions ... top environmental legislators by the nation’s foremost conservation organizations, will speak at the ...
(Date:6/30/2015)... , ... July 01, 2015 , ... Avid boxing style ... and Jimi Hendrix Singer Bowl concert posters. The Who and the Rascals also played ... According to Hawley, "The Doors played with the Who backing them up. The ...
(Date:6/30/2015)... Louis, Missouri (PRWEB) , ... July 01, 2015 , ... ... transvaginal mesh lawsuits being managed in a West Virginia federal court. The ... also set a trial date for the 26 cases.¹ , Carey Danis & Lowe ...
Breaking Medicine News(10 mins):Health News:WIU Crossroads School Chooses Help Alert Mobile Staff Duress Pendants from RF Technologies to Safeguard Staff and Students, De-escalate Altercations 2Health News:WIU Crossroads School Chooses Help Alert Mobile Staff Duress Pendants from RF Technologies to Safeguard Staff and Students, De-escalate Altercations 3Health News:Whiter Image Dental Offers New Customers Half-Off Teeth Whitening Kit 2Health News:Clean Drinking Water Now Available to Millions of Mexican Children as a Result of Partnership Between Seldon Technologies and Bebederos Ecologicos / Ottone Meloda 2Health News:Clean Drinking Water Now Available to Millions of Mexican Children as a Result of Partnership Between Seldon Technologies and Bebederos Ecologicos / Ottone Meloda 3Health News:Avid Boxing Style Rock Concert Poster Collector From Vintage Rock Posters Announces Search for 1968 Doors and Jimi Hendrix Singer Bowl Concert Posters 2Health News:Carey Danis & Lowe Comments on New Pretrial Order in Vaginal Mesh Lawsuit 2Health News:Carey Danis & Lowe Comments on New Pretrial Order in Vaginal Mesh Lawsuit 3
... N.Y., Oct. 8 Moog Inc. (NYSE:,MOG.A and ... are adopting,the Moog brand name. The organizations and ... to an expanded product portfolio within a,single, well-established ... continue to be associated with the,products, this event ...
... by Leading Architectural Firms, LISBON, Portugal ... weeks after,awarding two Johns Hopkins University scientists ... for their research in combating blindness, the,Antonio ... medical,research with the groundbreaking of its 300,000-square-foot ...
... safe substitutes for authentic,FDA approved injectables, NEW ... cosmetic injectables are a threat to your looks,and ... Safety. "The,growing acceptance of cosmetic injections for their ... cautions," says Coalition,leader, plastic surgeon Jeffrey Kenkel, MD ...
... Hodgkin lymphoma, a common form of cancer of the ... blood cells (B cells), but have lost a considerable ... phenotype and the characteristics of Hodgkin lymphoma cells are ... Delbrck Center for Molecular Medicine, MDC, Berlin-Buch and Charit ...
... of Defense has awarded The University of Texas Health ... conduct a multi-center clinical trial that could lead to ... both soldiers and civilians -- who require massive blood ... Sciences (CCTS) is contracting with the U.S. Army Institute ...
... closer to understanding the spread of deadly diseases such ... bacteria respond to stress. , The research, published in ... Science , details how a huge molecule called a ... , Scientists from the University of Newcastle in ...
Cached Medicine News:Health News:World Renowned Champalimaud Foundation Extends its Mission with Groundbreaking for Cutting-Edge Research Center 2Health News:World Renowned Champalimaud Foundation Extends its Mission with Groundbreaking for Cutting-Edge Research Center 3Health News:Illegal Botox Scammers a Public Threat 2Health News:Illegal Botox Scammers a Public Threat 3Health News:Illegal Botox Scammers a Public Threat 4Health News:Illegal Botox Scammers a Public Threat 5Health News:Hodgkin lymphoma -- new characteristics discovered 2Health News:Hodgkin lymphoma -- new characteristics discovered 3Health News:UT researchers to study massive transfusion at major trauma centers 2Health News:Protection for stressed-out bacteria identified 2
... The Apollo Knee System has been ... through range of motion of any fixed ... area and low contact stress under loading ... contributes to long-term effectiveness. The universal symmetrical ...
The Advance revision knee system was designed to address the unpredictable nature of revision knee arthroplasty by providing a wide variety of implant and instrument options....
The AGC dual articular knee is indicated for severe primary or revision cases and features a patented unique articulation which allows controlled rotation of the femoral component about a central piv...
... NexGen CRA femoral component is intended ... anteroposterior, and varus/valgus ligament stability, yet ... to inadequate bone stock. The NexGen ... a PMMA precoat surface. This device ...
Medicine Products: